241 related articles for article (PubMed ID: 28324595)
21. Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection.
Bonfanti JF; Roymans D
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):479-87. PubMed ID: 19562644
[TBL] [Abstract][Full Text] [Related]
22. A Druggable Pocket at the Nucleocapsid/Phosphoprotein Interaction Site of Human Respiratory Syncytial Virus.
Ouizougun-Oubari M; Pereira N; Tarus B; Galloux M; Lassoued S; Fix J; Tortorici MA; Hoos S; Baron B; England P; Desmaële D; Couvreur P; Bontems F; Rey FA; Eléouët JF; Sizun C; Slama-Schwok A; Duquerroy S
J Virol; 2015 Nov; 89(21):11129-43. PubMed ID: 26246564
[TBL] [Abstract][Full Text] [Related]
23. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients.
Liu V; Dhillon GS; Weill D
Transpl Infect Dis; 2010 Feb; 12(1):38-44. PubMed ID: 19761558
[TBL] [Abstract][Full Text] [Related]
24. Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection.
Sun Z; Wang Q; Jia R; Xia S; Li Y; Liu Q; Xu W; Xu J; Du L; Lu L; Jiang S
Viruses; 2015 Feb; 7(2):798-819. PubMed ID: 25690799
[TBL] [Abstract][Full Text] [Related]
25. Ongoing developments in RSV prophylaxis: a clinician's analysis.
Rezaee F; Linfield DT; Harford TJ; Piedimonte G
Curr Opin Virol; 2017 Jun; 24():70-78. PubMed ID: 28500974
[TBL] [Abstract][Full Text] [Related]
26. Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors.
Feng S; Li C; Chen D; Zheng X; Yun H; Gao L; Shen HC
Eur J Med Chem; 2017 Sep; 138():1147-1157. PubMed ID: 28772235
[TBL] [Abstract][Full Text] [Related]
27. Respiratory syncytial virus disease: update on treatment and prevention.
Krilov LR
Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875
[TBL] [Abstract][Full Text] [Related]
28. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
Resch B
Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
[TBL] [Abstract][Full Text] [Related]
29. Respiratory syncytial virus infections: characteristics and treatment.
Chidgey SM; Broadley KJ
J Pharm Pharmacol; 2005 Nov; 57(11):1371-81. PubMed ID: 16259768
[TBL] [Abstract][Full Text] [Related]
30. Respiratory syncytial virus infection in adult populations.
Walsh EE; Falsey AR
Infect Disord Drug Targets; 2012 Apr; 12(2):98-102. PubMed ID: 22335500
[TBL] [Abstract][Full Text] [Related]
31. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
Resch B; Egger B; Kurath-Koller S; Urlesberger B
Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
[TBL] [Abstract][Full Text] [Related]
32. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
33. Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery.
Heylen E; Neyts J; Jochmans D
Biochem Pharmacol; 2017 Mar; 127():1-12. PubMed ID: 27659812
[TBL] [Abstract][Full Text] [Related]
34. Antiviral effect of cimicifugin from Cimicifuga foetida against human respiratory syncytial virus.
Wang KC; Chang JS; Lin LT; Chiang LC; Lin CC
Am J Chin Med; 2012; 40(5):1033-45. PubMed ID: 22928833
[TBL] [Abstract][Full Text] [Related]
35. New strategies for control of respiratory syncytial virus infection.
Nokes JD; Cane PA
Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
[TBL] [Abstract][Full Text] [Related]
36. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines.
Fuentes S; Arenas D; Moore MM; Golding H; Khurana S
Vaccine; 2017 Jan; 35(4):694-702. PubMed ID: 27989627
[TBL] [Abstract][Full Text] [Related]
37. The Interferon Type I/III Response to Respiratory Syncytial Virus Infection in Airway Epithelial Cells Can Be Attenuated or Amplified by Antiviral Treatment.
McCutcheon KM; Jordan R; Mawhorter ME; Noton SL; Powers JG; Fearns R; Cihlar T; Perron M
J Virol; 2016 Feb; 90(4):1705-17. PubMed ID: 26608311
[TBL] [Abstract][Full Text] [Related]
38. Respiratory syncytial virus (RSV) infection in children with medical complexity.
Lim A; Butt ML; Dix J; Elliott L; Paes B
Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):171-176. PubMed ID: 30374685
[TBL] [Abstract][Full Text] [Related]
39. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients.
Hynicka LM; Ensor CR
Ann Pharmacother; 2012 Apr; 46(4):558-66. PubMed ID: 22395247
[TBL] [Abstract][Full Text] [Related]
40. Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.
Pickens JA; Tripp RA
Viruses; 2018 Jan; 10(1):. PubMed ID: 29361733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
